PortfoliosLab logo

Arbutus Biopharma Corporation (ABUS)

Equity · Currency in USD · Last updated Mar 28, 2023

Share Price Chart

Loading data...


The chart shows the growth of $10,000 invested in Arbutus Biopharma Corporation in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $4,347 for a total return of roughly -56.53%. All prices are adjusted for splits and dividends.

ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABUS

Arbutus Biopharma Corporation


Arbutus Biopharma Corporation had a return of 31.33% year-to-date (YTD) and 5.88% in the last 12 months. Over the past 10 years, Arbutus Biopharma Corporation had an annualized return of -4.23%, while the S&P 500 had an annualized return of 9.76%, indicating that Arbutus Biopharma Corporation did not perform as well as the benchmark.

1 month15.47%0.19%
6 months59.38%7.70%
1 year5.88%-12.45%
5 years (annualized)-10.08%8.78%
10 years (annualized)-4.23%9.76%

Monthly Returns Heatmap


Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Arbutus Biopharma Corporation Sharpe ratio is 0.02. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.

The chart below displays rolling 12-month Sharpe Ratio.

ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Dividend History

Arbutus Biopharma Corporation doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.

ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Arbutus Biopharma Corporation. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Arbutus Biopharma Corporation is 97.19%, recorded on Oct 9, 2019. The portfolio has not recovered from it yet.



To Bottom


To Recover



-97.19%Mar 12, 20141406Oct 9, 2019
-80.95%Jan 20, 2011213Nov 25, 2011457Sep 26, 2013670
-36.08%Nov 16, 201024Dec 20, 201020Jan 19, 201144
-31.5%Oct 8, 201346Dec 11, 201321Jan 13, 201467
-18.01%Feb 26, 20144Mar 3, 20142Mar 5, 20146
-9.03%Sep 27, 20132Sep 30, 20133Oct 3, 20135
-7.7%Jan 21, 20145Jan 27, 20143Jan 30, 20148
-6.4%Feb 21, 20141Feb 21, 20141Feb 24, 20142
-6.09%Feb 5, 20142Feb 6, 20143Feb 11, 20145
-5.73%Jan 14, 20141Jan 14, 20142Jan 16, 20143

Volatility Chart

Current Arbutus Biopharma Corporation volatility is 28.58%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.

ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)